From the Research
Mounjaro (tirzepatide) has been shown to reduce alcohol consumption in individuals with obesity, according to a recent study published in 2023 1. This medication works by mimicking hormones called GLP-1 and GIP, which regulate blood sugar and appetite, and may also affect the brain's reward pathways involved in alcohol cravings. Some key points to consider:
- The study found that participants taking tirzepatide had significantly lower self-reported intake of alcohol, drinks per drinking episode, and binge drinking odds compared to the control group 1.
- Typical dosing of Mounjaro starts at 2.5 mg weekly by injection, gradually increasing if needed.
- If you're struggling with alcohol use disorder, it's essential to discuss this potential off-label use with your healthcare provider, as they can determine if it's appropriate for your specific situation.
- Mounjaro should be used alongside other treatments for alcohol use disorder, such as counseling or support groups, rather than as a standalone solution.
- Common side effects of Mounjaro include nausea, diarrhea, and stomach discomfort, which should be monitored if prescribed. It's also important to note that while Mounjaro has shown promise in reducing alcohol consumption, it is not FDA-approved specifically for this purpose, and more research is needed to fully understand its effects on alcohol use disorder.